A large-scale genome study uncovered IL31 as a key genetic contributor to prurigo nodularis, linking it to immune-regulatory ...

Galderma日前宣布，欧盟已批准其白介素-31（IL-31）受体靶向单抗Nemluvio（nemolizumab），用于治疗中度至重度特应性皮炎和结节性瘙痒（prurigo nodularis ...

Prurigo nodularis is an inflammatory skin condition that causes the development of intensely itchy skin and bumps or lumps (nodules) on the legs, arms, upper back, or abdomen. This article ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

近日，该公司宣布，美国食品和药物管理局（FDA）已授予vixarelimab治疗结节性痒疹（prurigo nodularis，PN）相关瘙痒的突破性药物资格（BTD）。

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data ...

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas. 11 It is an ...

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis ...

Prurigo nodularis is a chronic inflammatory skin condition that causes extreme, persistent itching and lesions that can cover most of the body. The intense itch can severely undercut quality of ...

Last accessed April 2024 Kwatra SG, et al. Phase III trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579-89. doi: 10.1056/NEJMoa2301333 ...

For adult patients living with prurigo nodularis, dupilumab (Dupixent) was shown to significantly improve their skin lesions, quality of life (QOL), and itching, reports a new study in Anais ...